{
  "id": 11136475,
  "title": "JPMorgan initiates Kura Oncology stock with overweight rating",
  "url": "https://urgent.news/2026/10/01/jpmorgan-initiates-kura-oncology-stock-with-overweight-rating",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-10-01T07:32:53.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/jpmorgan-initiates-kura-oncology-stock-with-overweight-rating-93CH-4926444"
  },
  "original_language": "en",
  "account": "JPMorgan boosted its rating on Kura Oncology (NASDAQ:KURA) to \"overweight\" and set a price target of $30.00, indicating an estimated 180% upside potential from the current stock price of $10.71. The company's market capitalization is valued at $953 million, with consensus analyst opinions favoring a \"strong buy\" rating, with target prices ranging from $15 to $76. JPMorgan's focus is on Kura Oncology's development of Komzifti (ziftomenib) for relapsed/refractory NPM1-mutant AML, a drug with a potential monotherapy or combination therapy role across existing AML therapies. The firm highlights several advantages of ziftomenib, including a clean label, low differentiation syndrome, and no QTc black-box warning, which sets it apart from other menin inhibitors. JPMorgan estimates the drug's peak sales could reach approximately $1.5 billion for both the relapsed/refractory and first-line NPM1-mutant AML markets. Additionally, the company has developed darlifarnib, a next-generation farnesyl transferase inhibitor, which extends Kura's reach beyond a single menin inhibitor launch. The firm anticipates a path to third-line and later renal cell carcinoma indications, which could provide a total addressable market of about $2 billion, with a potential second-line opportunity of around $6 billion. Despite the current stock valuation only covering the approved relapsed/refractory NPM1-mutant population, JPMorgan believes Kura Oncology shares have significant upside potential. Eight analysts have recently revised their earnings estimates upward for the next reporting period, reinforcing the bullish outlook. Strong stock momentum is evident, with a 28% increase over the past six months. Investors may find additional insights in the Pro Research Report on KURA, part of 1,400+ US equities covered with expert analysis and actionable intelligence. Recent financial results for Kura Oncology exceeded analyst expectations, with an adjusted loss of $0.77 per share compared to the expected $0.88 loss and revenue of $20.87 million, slightly above the anticipated $20.16 million. This growth is attributed to early sales of KOMZIFTI. The stock also received a boost following insider purchases by the company's President and CEO, Troy Edward Wilson, who acquired a total of 200,000 shares at weighted average prices of $11.12 and $12.39 per share.",
  "summary": null,
  "key_points": [
    "JPMorgan upgrades Kura Oncology stock to overweight rating",
    "Sets price target of $30.00, indicating 180% upside potential",
    "Focus on Komzifti (ziftomenib) for NPM1-mutant AML treatment"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "Enliven Therapeutics stock initiated at Overweight by JPMorgan",
        "url": "https://urgent.news/2026/10/01/enliven-therapeutics-stock-initiated-at-overweight-by-jpmorgan",
        "published": "2026-10-01T07:32:47.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}